The interleukin-1α precursor is biologically active and is likely a key alarmin in the IL-1 family of cytokines

Frontiers in Immunology

Volumn 4, Issue NOV, 2013, Pages

  Kim, Busun ^a   Lee, Youngmin ^b   Kim, Eunsom ^c   Kwak, Areum ^c   Ryoo, Soyoon ^c   Bae, Seung Hyeon ^d   Azam, Tania ^a   Kim, Soohyun ^c   Dinarello, Charles A ^a,c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Inje University College of Medicine   (South Korea)

^c Konkuk University   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

Author keywords

DAMPs; IL 1 family cytokine; Precursor IL 1 ; Recombinant protein; Sterile inflammation

Indexed keywords

EID: 84890420757     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00391     Document Type: Article

References (40)

1. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol (2009) 27:519-50. doi: 10.1146/annurev.immunol.021908.132612
2. Stevenson FT, Turck J, Locksley RM, Lovett DH. The N-terminal propiece of interleukin 1 alpha is a transforming nuclear oncoprotein. Proc Natl Acad Sci U S A (1997) 94(2):508-13. doi:10.1073/pnas.94.2.508
3. Werman A, Werman-Venkert R, White R, Lee JK, Werman B, Krelin Y, et al. The precursor form of IL-1alpha is an intracrine proinflammatory activator of transcription. Proc Natl Acad Sci U S A (2004) 101(8):2434-9. doi:10.1073/pnas.0308705101
4. Cohen I, Rider P, Carmi Y, Braiman A, Dotan S, White MR, et al. Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation. Proc Natl Acad Sci U S A (2010) 107(6):2574-9. doi:10.1073/pnas.0915018107
5. Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L, et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci U S A (2007) 104(1):282-7. doi:10.1073/pnas.0606854104
6. Hong J, Bae S, Jhun H, Lee S, Choi J, Kang T, et al. Identification of constitutively active interleukin 33 (IL-33) splice variant. J Biol Chem (2011) 286(22):20078-86. doi:10.1074/jbc.M111.219089
7. Lefrancais E, Roga S, Gautier V, Gonzalez-de-Peredo A, Monsarrat B, Girard JP, et al. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc Natl Acad Sci U S A (2012) 109(5):1673-8. doi:10.1073/pnas.1115884109
8. Coeshott C, Ohnemus C, Pilyavskaya A, Ross S, Wieczorek M, Kroona H, et al. Converting enzyme-independent release of TNFa and IL-1beta from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase-3. Proc Natl Acad Sci U S A (1999) 96:6261-6. doi:10.1073/pnas.96.11.6261
9. Joosten LA, Netea MG, Fantuzzi G, Koenders MI, Helsen MM, Sparrer H, et al. Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta. Arthritis Rheum (2009) 60(12):3651-62. doi:10.1002/art.25006
10. Sugawara S, Uehara A, Nochi T, Yamaguchi T, Ueda H, Sugiyama A, et al. Neutrophil proteinase 3-mediated induction of bioactive IL-18 secretion by human oral epithelial cells. J Immunol (2001) 167(11):6568-75.
11. Oppenheim JJ, Yang D. Alarmins: chemotactic activators of immune responses. Curr Opin Immunol (2005) 17(4):359-65. doi:10.1016/j.coi.2005.06.002
12. Rubartelli A, Lotze MT. Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol (2007) 28(10):429-36. doi:10.1016/j.it.2007.08.004
13. Manzer R, Dinarello CA, McConville G, Mason RJ. Ozone exposure of macrophages induces an alveolar epithelial chemokine response through IL-1alpha. Am J Respir Cell Mol Biol (2008) 38(3):318-23. doi:10.1165/rcmb.2007-0250OC
14. Portnoy J, Pan T, Dinarello CA, Shannon JM, Westcott JY, Zhang L, et al. Alveolar type II cells inhibit fibroblast proliferation: role of IL-1alpha. Am J Physiol Lung Cell Mol Physiol (2006) 290(2):L307-16. doi:10.1152/ajplung.00102.2005
15. Chen CJ, Kono H, Golenbock D, Reed G, Akira S, Rock KL. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med (2007) 13(7):851-6. doi:10.1038/nm1603
16. Rider P, Carmi Y, Guttman O, Braiman A, Cohen I, Voronov E, et al. IL-1α and IL-1β recruit different myeloid cells and promote different stages of sterile inflammation. J Immunol (2011) 187:4835-43. doi:10.4049/jimmunol.1102048
17. Sutton C, Brereton C, Keogh B, Mills KH, Lavelle EC. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med (2006) 203(7):1685-91. doi:10.1084/jem.20060285
18. Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KH. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity (2009) 31(2):331-41. doi:10.1016/j.immuni.2009.08.001
19. Bae S, Kang T, Hong J, Lee S, Choi J, Jhun H, et al. Contradictory functions (activation/termination) of neutrophil proteinase 3 enzyme (PR3) in interleukin-33 biological activity. J Biol Chem (2012) 287(11):8205-13. doi:10.1074/jbc.M111.295055
20. Kim KH, Shim JH, Seo EH, Cho MC, Kang JW, Kim SH, et al. Interleukin-32 monoclonal antibodies for immunohistochemistry, western blotting, and ELISA. J Immunol Methods (2008) 333(1-2):38-50. doi:10.1016/j.jim.2007.12.017
21. Colotta F, Re F, Muzio M, Bertini R, Polentarutti N, Sironi M, et al. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science (1993) 261:472-5. doi:10.1126/science.8332913
22. Symons JA, Young PA, Duff GW. Differential release and ligand binding of type II IL-1 receptors. Cytokine (1994) 6:555. doi:10.1016/1043-4666(94)90181-3 (abs)
23. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov (2012) 11(8):633-52. doi:10.1038/nrd3800
24. Ikejima T, Ikusawa S, Ghezzi P, van der Meer JWM, Dinarello CA. Interleukin-1 induces tumor necrosis factor (TNF) in human peripheral blood mononuclear cells in vitro and a circulating TNF-like activity in rabbits. J Infect Dis. (1990) 162:215-21. doi:10.1093/infdis/162.1.215
25. Wang D, Zhang S, Li L, Liu X, Mei K, Wang X. Structural insights into the assembly and activation of IL-1beta with its receptors. Nat Immunol (2010) 11(10):905-11. doi:10.1038/ni.1925
26. Bonilla WV, Frohlich A, Senn K, Kallert S, Fernandez M, Johnson S, et al. The alarmin interleukin-33 drives protective antiviral CD8(+) T cell responses. Science (2012) 335(6071):984-9. doi:10.1126/science.1215418
27. Byrne SN, Beaugie C, O'Sullivan C, Leighton S, Halliday GM. The immune-modulating cytokine and endogenous alarmin interleukin-33 is upregulated in skin exposed to inflammatory UVB radiation. Am J Pathol (2011) 179(1):211-22. doi:10.1016/j.ajpath.2011.03.010
28. Cevikbas F, Steinhoff M. IL-33: a novel danger signal system in atopic dermatitis. J Invest Dermatol (2012) 132(5):1326-9. doi:10.1038/jid.2012.66
29. Haraldsen G, Balogh J, Pollheimer J, Sponheim J, Kuchler AM. Interleukin-33-cytokine of dual function or novel alarmin? Trends Immunol (2009) 30(5):227-33. doi:10.1016/j.it.2009.03.003
30. Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel "alarmin"? PLoS One (2008) 3(10):e3331. doi:10.1371/journal.pone.0003331
31. Wong CK, Leung KM, Qiu HN, Chow JY, Choi AO, Lam CW. Activation of eosinophils interacting with dermal fibroblasts by pruritogenic cytokine IL-31 and alarmin IL-33: implications in atopic dermatitis. PLoS One (2012) 7(1):e29815. doi:10.1371/journal.pone.0029815
32. Harris HE, Raucci A. Alarmin(g) news about danger: workshop on innate danger signals and HMGB1. EMBO Rep (2006) 7(8):774-8. doi:10.1038/sj.embor.7400759
33. Gayle RB III, Poindexter K, Cosman D, Dower SK, Gillis S, Hopp T, et al. Identification of regions in interleukin-1 alpha important for activity. J Biol Chem (1993) 268(29):22105-11.
34. Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, et al. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature (1992) 356(6372):768-74. doi:10.1038/356768a0
35. Fantuzzi G, Ku G, Harding MW, Livingston DL, Sipe JD, Kuida K, et al. Response to local inflammation of IL-1b converting enzyme-deficient mice. J Immunol (1997) 158:1818-24.
36. Lomedico PT, Gubler R, Hellmann CP, Dukovich M, Giri JG, Pan YE, et al. Cloning and expression of murine interleukin-1 cDNA in Escherichia coli. Nature (1984) 312:458-62. doi:10.1038/312458a0
37. Zheng Y, Humphry M, Maguire JJ, Bennett MR, Clarke MC. Intracellular interleukin-1 receptor 2 binding prevents cleavage and activity of interleukin-1alpha, controlling necrosis-induced sterile inflammation. Immunity (2013) 38(2):285-95. doi:10.1016/j.immuni.2013.01.008
38. Berda-Haddad Y, Robert S, Salers P, Zekraoui L, Farnarier C, Dinarello CA, et al. Sterile inflammation of endothelial cell-derived apoptotic bodies is mediated by interleukin-1alpha. Proc Natl Acad Sci U S A (2011) 108(51):20684-9. doi:10.1073/pnas.1116848108
39. Hong DS, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, et al. A phase I study of MABp1, a first-in-human, first-true human monoclonal antibody against the IL-1 in patients with advanced cancers. Mol Cancer Ther (2011) 10(Suppl 1):A211. doi:10.1158/1535-7163.TARG-11-A211
40. Hong K, Lee Y, Lee S, Hong S, Bae S, Hong J, et al. The inhibitory function of Fc-ST2 depends on cell type; IL-1RAcP and ST2 are necessary but insufficient for IL-33 activity. Immunol Res (2013) 56(1):122-30. doi:10.1007/s12026-013-8388-9